These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Search MEDLINE/PubMed


  • Title: Lack of association between seroconversion and catch-up growth in children with celiac disease.
    Author: Zung A, Kori M.
    Journal: J Pediatr Endocrinol Metab; 2012; 25(1-2):131-7. PubMed ID: 22570962.
    Abstract:
    OBJECTIVE: To assess the association between seroconversion and catch-up growth during the first year of a gluten-free diet (GFD) program in children with celiac disease (CD). METHODS: All prepubertal and biopsy-proven children diagnosed with CD between January 1999 and August 2009 were included in a retrospective study (n=55). Growth parameters and celiac antibodies were documented before and after 6 (period 1) and 12 months (period 2) of GFD, respectively. RESULTS: Mean height velocity-standard deviation score (SDS) was significantly higher in period 1 compared with that in period 2 (2.90 +/- 3.20 vs. 0.20 +/- 2.08, p<0.001) irrespective of the serology status, with marginal difference in mean weight-SDS gain (p=0.074). Mean levels of height velocity-SDS and the weight-SDS gain were similar in the seropositive and seronegative groups in both periods of the study. Mean height-SDS and weight-SDS levels after 6 months were higher than those in baseline levels, both in seropositive (-0.47 +/- 0.91 vs. -0.82 +/- 0.82, p<0.001 and -0.59 +/- 1.17 vs. -1.11 +/- 1.33, p<0.001, respectively) and seronegative patients (-1.02 +/- 1.14 vs. -1.50 +/- 1.12, p<0.001 and -1.19 +/- 1.27 vs. -1.45 +/- 1.40, p=0.048, respectively). These growth parameters were higher at the end compared with the beginning of period 2, but only in seropositive patients. CONCLUSIONS: The most remarkable catch-up growth in children with CD can be expected during the first 6 months of GFD, irrespective of the serology status.
    [Abstract] [Full Text] [Related] [New Search]